SCHEMBL4209197

SCHEMBL4209197

ON=C(Cc1ccccc1)c1ccc(OCc2ccccc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A1 P22736 1/20 0.58
NR4A2 P43354 1/20 0.58
NR4A3 Q92570 1/20 0.58
SMN1; SMN2 Q16637 3/20 0.57
KDM4E B2RXH2 1/20 0.57
LMNA P02545 1/20 0.56
CYP1A2 P05177 1/20 0.56
PTGS1 P23219 1/20 0.56
SLC6A2 P23975 1/20 0.56
CYP2C19 P33261 1/20 0.56
PTGS2 P35354 1/20 0.56
SLC6A3 Q01959 1/20 0.56
HIF1A Q16665 1/20 0.56
HDAC6 Q9UBN7 1/20 0.56
MAOB P27338 2/20 0.55
PARP10 Q53GL7 1/20 0.55
SRD5A2 P31213 1/20 0.54
PLA2G4B P0C869 1/20 0.51
RAB9A P51151 3/20 0.50
NPC1 O15118 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4209193 1.00 NR4A1 (0.58) NR4A1NR4A2NR4A3SMN1; SMN2KDM4E
SCHEMBL5706491 0.87 NR4A1 (0.58) NR4A1NR4A2NR4A3SMN1; SMN2KDM4E
SCHEMBL17276674 0.86 MAOB (0.58) NR4A1NR4A2NR4A3SMN1; SMN2LMNA
SCHEMBL7908828 0.84 NR4A1 (0.55) NR4A1NR4A2NR4A3SMN1; SMN2KDM4E
SCHEMBL4216593 0.82 SMN1; SMN2 (0.84) SMN1; SMN2KDM4ERAB9ANPC1MAPT
SCHEMBL4216595 0.82 SMN1; SMN2 (0.84) SMN1; SMN2KDM4ERAB9ANPC1MAPT
SCHEMBL8407033 0.81 MGLL (0.58) SMN1; SMN2KDM4ELMNACYP1A2PTGS1
SCHEMBL257218 0.80 CTSL (0.55) SMN1; SMN2KDM4E
SCHEMBL4586157 0.80 CTSL (0.55) SMN1; SMN2KDM4E
SCHEMBL4586154 0.80 CTSL (0.55) SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090131397-A1 ESTROGEN MODULATORS PFIZER INC. 2009-05-21 US disclosed
US-7470715-B2 Estrogen modulators PFIZER INC. (US) 2008-12-30 US disclosed
EP-1966170-A2 ESTROGEN MODULATORS Pfizer Products Inc. (US) 2008-09-10 EP disclosed
WO-2007072164-A2 ESTROGEN MODULATORS PFIZER PRODUCTS INC. (US) 2007-06-28 WO disclosed
US-20070149564-A1 ESTROGEN MODULATORS PFIZER INC. (US) 2007-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131397-A1 ESTROGEN MODULATORS ESR2, GPER1, ESR1 NR4A1 68/4885NR4A2 50/4885NR4A3 32/4885
US-20070149564-A1 ESTROGEN MODULATORS ESR2, GPER1, ESR1 NR4A1 68/4885NR4A2 50/4885NR4A3 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.